Traumatic Brain Injury - Pipeline Review, H1 2018 - Product Image

Traumatic Brain Injury - Pipeline Review, H1 2018

  • ID: 4451672
  • Report
  • 270 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ALSP Inc
  • CalciMedica Inc
  • Ischemix Inc
  • Neurofx Inc
  • NuvOx Pharma LLC
  • Sage Therapeutics Inc
  • MORE
Traumatic Brain Injury - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2018, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 10, 60 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System)
  • The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ALSP Inc
  • CalciMedica Inc
  • Ischemix Inc
  • Neurofx Inc
  • NuvOx Pharma LLC
  • Sage Therapeutics Inc
  • MORE
Introduction

Traumatic Brain Injury - Overview

Traumatic Brain Injury - Therapeutics Development

Traumatic Brain Injury - Therapeutics Assessment

Traumatic Brain Injury - Companies Involved in Therapeutics Development

Traumatic Brain Injury - Drug Profiles

Traumatic Brain Injury - Dormant Projects

Traumatic Brain Injury - Discontinued Products

Traumatic Brain Injury - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Traumatic Brain Injury, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Traumatic Brain Injury - Pipeline by ALSP Inc, H1

Traumatic Brain Injury - Pipeline by Aptinyx Inc, H1

Traumatic Brain Injury - Pipeline by Athersys Inc, H1

Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1

Traumatic Brain Injury - Pipeline by CalciMedica Inc, H1

Traumatic Brain Injury - Pipeline by Cantex Pharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Cognosci Inc, H1

Traumatic Brain Injury - Pipeline by Complement Pharma BV, H1

Traumatic Brain Injury - Pipeline by Eisai Co Ltd, H1

Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1

Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1

Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1

Traumatic Brain Injury - Pipeline by Ischemix Inc, H1

Traumatic Brain Injury - Pipeline by JT Pharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1

Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1

Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1

Traumatic Brain Injury - Pipeline by MandalMed Inc, H1

Traumatic Brain Injury - Pipeline by Mapreg SAS, H1

Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1

Traumatic Brain Injury - Pipeline by Neurofx Inc, H1

Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1

Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1

Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1

Traumatic Brain Injury - Pipeline by NoNO Inc, H1

Traumatic Brain Injury - Pipeline by Noxopharm Ltd, H1

Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1

Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Prevacus Inc, H1

Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1

Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by Rubicon Biotechnology Inc, H1

Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1

Traumatic Brain Injury - Pipeline by SanBio Inc, H1

Traumatic Brain Injury - Pipeline by Scythian Biosciences Corp, H1

Traumatic Brain Injury - Pipeline by Silver Creek Pharmaceuticals Inc, H1

Traumatic Brain Injury - Pipeline by STATegics Inc, H1

Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1

Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1

Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1

Traumatic Brain Injury - Pipeline by Therapix Biosciences Ltd, H1

Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1

Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1

Traumatic Brain Injury - Dormant Projects, H1

Traumatic Brain Injury - Discontinued Products, H1

List of Figures

Number of Products under Development for Traumatic Brain Injury, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ALSP Inc
  • Aptinyx Inc
  • Athersys Inc
  • Beech Tree Labs Inc
  • CalciMedica Inc
  • Cantex Pharmaceuticals Inc
  • Cognosci Inc
  • Complement Pharma BV
  • Eisai Co Ltd
  • Eustralis Pharmaceuticals Ltd
  • Intellect Neurosciences Inc
  • International Stem Cell Corp
  • Ischemix Inc
  • JT Pharmaceuticals Inc
  • Karyopharm Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Levolta Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • MandalMed Inc
  • Mapreg SAS
  • Neuren Pharmaceuticals Ltd
  • Neurofx Inc
  • NeuroNascent Inc
  • NeuroVive Pharmaceutical AB
  • New World Laboratories Inc
  • NoNO Inc
  • Noxopharm Ltd
  • NuvOx Pharma LLC
  • Oxeia Biopharmaceuticals Inc
  • Prevacus Inc
  • QR Pharma Inc
  • RegeneRx Biopharmaceuticals Inc
  • Rubicon Biotechnology Inc
  • Sage Therapeutics Inc
  • SanBio Inc
  • Scythian Biosciences Corp
  • Silver Creek Pharmaceuticals Inc
  • STATegics Inc
  • Stemedica Cell Technologies Inc
  • SynZyme Technologies LLC
  • Tetra Discovery Partners LLC
  • Therapix Biosciences Ltd
  • Vasopharm GmbH
  • VG Life Sciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll